Latest:
Oncology Practice Vitality Depends on Leadership
The pace of consolidation shows no sign of slowing down, and this trend also applies to oncology, as more and more community-based oncology practices are joining large health systems.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Nicole Lamanna, MD
Nicole Lamanna, MD, is a hematologic oncologist at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center
Latest:
Recognizing BTKi Resistance in CLL—Incorporating Pirtobrutinib in Relapsed/Refractory Disease
Panelists discuss how Bruton tyrosine kinase (BTK) resistance mutation testing is routinely performed at disease progression, but currently doesn’t change treatment decisions because pirtobrutinib shows comparable efficacy regardless of mutation status. However, high-level mutations (C481S or L528W) might favor venetoclax-based therapy over pirtobrutinib in second-line treatment. The panelists also emphasize the importance of patient education; approximately one-third of progressive patients lack detectable resistance mutations yet still require treatment changes based on clinical progression rather than molecular findings.
Niels Reinmuth, MD, PhD
Latest:
PD-L1 Testing in NSCLC: A Practical Guide for Oncologists
Experts discuss the practical use and limitations of PD-L1 testing in NSCLC. They confirm that testing is standard for all patients, but note results can vary between different PD-L1 test platforms, requiring quality-controlled assays.
Nikhil C. Munshi, MD
Latest:
Dr Munshi on the Background of the CARTITUDE-1 Trial in Multiple Myeloma
Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.
Nilanjan Ghosh, MD, PhD
Latest:
Future Perspectives for the Treatment of Relapsed/Refractory DLBCL
A reflection on key accomplishments in DLBCL treatment, highlighting pivotal developments that have shaped clinical practice, followed by a look ahead to 2025, focusing on areas poised for significant progress and personal goals for the coming year
Nils D. Arvold, MD
Latest:
The Role of Radiation in the Management of Brain Metastases
In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.
Nirav N. Shah, MD
Nirav N. Shah, MD, is an associate professor of medicine in the Division of Hematology and Oncology at Medical College of Wisconsin.
Latest:
Dr Shah on the Clinical Implications and Future Directions of Zamto-Cel in R/R DLBCL
Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.